Senti Biosciences (SNTI) Competitors $2.13 -0.19 (-8.19%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.88 +0.75 (+35.16%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. PRQR, SLRN, TVGN, MNPR, SXTC, SLS, EDIT, DSGN, TVRD, and SCPHShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include ProQR Therapeutics (PRQR), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Monopar Therapeutics (MNPR), China SXT Pharmaceuticals (SXTC), SELLAS Life Sciences Group (SLS), Editas Medicine (EDIT), Design Therapeutics (DSGN), Tvardi Therapeutics (TVRD), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors ProQR Therapeutics Acelyrin Semper Paratus Acquisition Monopar Therapeutics China SXT Pharmaceuticals SELLAS Life Sciences Group Editas Medicine Design Therapeutics Tvardi Therapeutics scPharmaceuticals Senti Biosciences (NASDAQ:SNTI) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Does the media refer more to SNTI or PRQR? In the previous week, ProQR Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 4 mentions for ProQR Therapeutics and 2 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.94 beat ProQR Therapeutics' score of 0.74 indicating that Senti Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of SNTI or PRQR? 25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate SNTI or PRQR? Senti Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 299.06%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 244.83%. Given Senti Biosciences' higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has higher earnings & valuation, SNTI or PRQR? ProQR Therapeutics has higher revenue and earnings than Senti Biosciences. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenti Biosciences$2.56M21.70-$52.79M-$10.84-0.20ProQR Therapeutics$20.46M11.93-$30.04M-$0.35-6.63 Is SNTI or PRQR more profitable? Senti Biosciences has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. ProQR Therapeutics' return on equity of -53.49% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Senti BiosciencesN/A -177.24% -67.38% ProQR Therapeutics -157.04%-53.49%-22.07% Which has more volatility & risk, SNTI or PRQR? Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. SummaryProQR Therapeutics beats Senti Biosciences on 11 of the 17 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.51M$2.96B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-0.2020.8528.1820.27Price / Sales21.70289.03428.7098.48Price / CashN/A42.8637.4658.16Price / Book0.407.638.045.49Net Income-$52.79M-$55.05M$3.19B$250.45M7 Day Performance-5.96%8.43%3.62%4.79%1 Month Performance-25.52%5.42%4.06%7.68%1 Year Performance-33.44%2.03%30.00%16.43% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.2013 of 5 stars$2.13-8.2%$8.50+299.1%-32.0%$60.51M$2.56M-0.204Analyst UpgradePRQRProQR Therapeutics2.5389 of 5 stars$2.14-1.8%$8.00+273.8%+34.1%$229.36M$20.46M-6.11180Analyst ForecastSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135TVGNSemper Paratus Acquisition4.0446 of 5 stars$1.20-3.2%$10.00+733.3%+70.0%$228.03MN/A0.003Gap DownMNPRMonopar Therapeutics2.0345 of 5 stars$37.20+2.6%$60.00+61.3%+924.0%$221.68MN/A-10.6910Analyst RevisionSXTCChina SXT Pharmaceuticals0.8918 of 5 stars$1.69-10.1%N/A-81.6%$218.13M$1.93M0.0090Gap DownSLSSELLAS Life Sciences Group0.3439 of 5 stars$2.17flatN/A+60.0%$216.52M$1M-5.7110High Trading VolumeEDITEditas Medicine4.2772 of 5 stars$2.54-1.2%$4.70+85.0%-47.3%$215.14M$32.31M-0.84230DSGNDesign Therapeutics0.637 of 5 stars$3.54-6.1%$4.00+13.0%-7.5%$214.02MN/A-3.5840News CoveragePositive NewsTVRDTvardi TherapeuticsN/A$21.52-4.2%$71.50+232.2%N/A$210.25M$7.14M0.0080News CoverageAnalyst ForecastAnalyst RevisionGap UpSCPHscPharmaceuticals4.5058 of 5 stars$3.86-2.8%$14.00+262.7%-4.8%$209.58M$36.33M-2.0230Positive News Related Companies and Tools Related Companies ProQR Therapeutics Alternatives Acelyrin Alternatives Semper Paratus Acquisition Alternatives Monopar Therapeutics Alternatives China SXT Pharmaceuticals Alternatives SELLAS Life Sciences Group Alternatives Editas Medicine Alternatives Design Therapeutics Alternatives Tvardi Therapeutics Alternatives scPharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNTI Stock Alerts